|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
6.430 USD |
0.00% | +8.98% | -26.18% | |
April 28, 2025 at 08:20 am EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Kura Oncology Announces First Patients Dosed In Phase 1 Combination Trial Of Ziftomenib For The Treatment Of Advanced Gist |
08:20am |
RE |
|
Kura Oncology Submits Ziftomenib NDA to FDA for Treating Acute Myeloid Leukemia |
Apr. 08 |
MT |
|
Kura Oncology, Inc. Announce Submission of New Drug Application for Ziftomenib to FDA |
Apr. 08 |
CI |
|
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
Apr. 04 |
RE |
|
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting |
Mar. 26 |
RE |
|
Kura Oncology, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-11-2025 09:30 AM |
Mar. 11 |
|
|
UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating |
Mar. 06 |
MT |
|
Kura Oncology, Inc., Q4 2024 Earnings Call, Feb 26, 2025 |
Feb. 26 |
|
|
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 26 |
CI |
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
Feb. 07 |
RE |
|
Wedbush Adjusts Kura Oncology’s Price Target to $26 From $34, Maintains Outperform Rating |
Feb. 06 |
MT |
|
Kura Oncology, Inc., Kyowa Kirin Co., Ltd. – Special Call |
Feb. 05 |
|
|
Kura Oncology And Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial |
Feb. 05 |
RE |
|
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs |
Feb. 05 |
CI |
|
Kura Oncology Promotes Mollie Leoni to Chief Medical Officer |
Jan. 06 |
MT |
|
Kura Oncology, Inc. Announces Senior Executive Promotions |
Jan. 06 |
CI |
|
Kura Oncology, Inc. – Special Call |
Dec. 09 |
|
|
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting |
Dec. 09 |
CI |
|
Health Care Climbs After Novartis Earnings – Health Care Roundup |
Nov. 21 |
DJ |
|
Wedbush Lowers Price Target on Kura Oncology to $34 From $37, Keeps Outperform Rating |
Nov. 21 |
MT |
|
Kura Oncology and Kyowa Kirin Announces Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias |
Nov. 20 |
CI |
|
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy |
Nov. 20 |
RE |
|
Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug |
Nov. 20 |
MT |
|
Kura Oncology, Inc., Kyowa Kirin Co., Ltd. – Special Call |
Nov. 20 |
KURA: Dynamic Chart
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
More about the company
Buy
Average target price
28.00USD
Spread / Average Target
+335.46%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
